White & Case advises Adelis on sale of majority stake in Europa Biosite to EQT Healthcare Growth

Global law firm White & Case LLP has advised Adelis on the sale of its majority stake in life science research reagents specialist distributor Europa Biosite to EQT Healthcare Growth.

Following its acquisition by Adelis in 2021, Europa Biosite has executed an international buy-and-build strategy, acquiring five companies in four years and creating a pan-European commercial footprint. It has established a position as the leading specialist distributor in its field, offering innovative products to thousands of life science researchers across the continent.

Adelis is a private equity firm managing approximately €4.5 billion in capital. Since raising its first fund in 2013, Adelis has made 47 platform investments and more than 270 add-on acquisitions.

Europa Biosite is a specialist distributor of life science research reagents with 180 employees in 17 countries across Europe and North America. Carrying a portfolio of more than ten million SKUs, it supports more than 60,000 researchers across Europe and North America in reaching their research objectives.

The White & Case team in Stockholm which advised on the transaction was led by partners Shoan Panahi and Sebastian Wallin (both Stockholm) and included partners Oscar Liljeson (Stockholm), Bethany Hills (New York) and Michael Engel (London), counsel Katrin Helle (Berlin) and associates Anders Westling, Matilda Högberg, Carl Runesson, Janina Stjernqvist, Tintin Persson, Karl Nordlin, Filip Karlsson and Emelie Söderman (all Stockholm).

Press contact
For more information please speak to your local media contact.